Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +75

Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait”

AI-generated analysis

📉 Jim Cramer notes Becton, Dickinson (BDX) is trading at the lowest valuation level he has ever seen for the stock.

📈 The company recently reported a strong quarter with a significant beat in both top-line and bottom-line earnings.

🚀 Management raised its full-year earnings forecast following the positive results.

🤖 BDX is benefiting from technology that enables hospitals to perform more tasks with fewer staff members.

⏳ Cramer advises investors to buy some shares now and wait to see if the stock oversells further before adding more.

⚠️ He warns that increased AI-related spending could create near-term headwinds for the broader market.

🧠 While acknowledging BDX's investment potential, Cramer suggests other AI stocks may offer higher returns in a shorter timeframe.

📊 The stock rose nearly 6% on the day of the earnings report despite a generally poor market performance.

🏥 Becton, Dickinson sells medical supplies, diagnostic tools, and lab equipment to healthcare professionals and researchers.

📅 This commentary was published on June 6, 2026, following the May 7 earnings episode discussion.

Bullish Signals
  • Becton, Dickinson and Company (NYSE: BDX) delivered a strong quarter with a huge top and bottom line beat.
  • Management raised the full-year earnings forecast following the recent results.
  • The stock surged nearly 6% on the day of the earnings release despite broader market weakness.
  • Jim Cramer highlighted that the company is selling at the lowest level he has ever seen, indicating a significant undervaluation opportunity.
  • The company demonstrated excellent execution across all business segments.
  • BDX is benefiting from technology advancements that enable hospitals to do more with fewer people.
Full Analysis
Jim Cramer expressed a bullish view on Becton, Dickinson and Company (NYSE: BDX) during an appearance on his show, noting that the stock is trading at what he considers its lowest market level in years. He advised investors to purchase shares now and wait for potential further declines, describing the valuation as very inexpensive. Cramer highlighted a recent strong quarterly performance where the company significantly beat earnings expectations on both the top and bottom lines. Following this positive earnings report, management raised their full-year earnings forecast, which contributed to a nearly 6% surge in the stock price despite broader market weakness. Cramer praised BDX's execution and noted that the company is benefiting from technology advancements that allow hospitals to operate more efficiently with fewer staff members. While acknowledging the investment potential of BDX, he contrasted it with other AI-focused stocks, suggesting that some pure-play AI companies might offer higher returns over a shorter timeframe. He specifically mentioned a hypothetical "cheapest AI stock" with exaggerated upside potential as an alternative for investors seeking greater growth, though this was framed as a promotional comparison rather than a direct critique of BDX's fundamentals. The core takeaway is Cramer's conviction that BDX is undervalued and well-positioned due to its recent operational success and earnings beat.